Is the GAIN Act a turning point in new antibiotic discovery? - Test2 - elhamkhani - TriplyDB

Is the GAIN Act a turning point in new antibiotic discovery?

Is the GAIN Act a turning point in new antibiotic discovery?

http://www.wikidata.org/entity/Q42268705

about

Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics Antibiotics: An irresistible newcomer.Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.Synthesis and biological evaluation of pyrazolopyrimidines as potential antibacterial agents The Response Regulator BfmR Is a Potential Drug Target for Acinetobacter baumannii.Targeted Treatment for Bacterial Infections: Prospects for Pathogen-Specific Antibiotics Coupled with Rapid Diagnostics β-Lactamase inhibitors: a review of the patent literature (2010 - 2013).Taking aim at wall teichoic acid synthesis: new biology and new leads for antibiotics.Genomic tools to profile antibiotic mode of action.Metabolic suppression identifies new antibacterial inhibitors under nutrient limitation.What if there were no new antibiotics? A look at alternatives.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Digging for new solutions.Antibiotic research and development: business as usual?CHEMICAL CHARACTERIZATION AND EVALUATION OF ANTIBACTERIAL, ANTIFUNGAL, ANTIMYCOBACTERIAL, AND CYTOTOXIC ACTIVITIES OF Talinum paniculatum Patent Protection for Microbial Technologies.Editorial to the themed issue on focus on infectious disease.Encouraging Antibiotic Development and Endorsing Conservation: Tandem Approaches to Our Declining Antibiotic Reserves.

P2860

Q26740597-799C271B-4138-40D9-A76B-FF97C4E96B7B Q34456690-109F3F92-53D3-4C1D-A2C5-2397C563F5BF Q35023680-6AF6C327-27DE-41C8-8EF2-8BA3F56A7FF1 Q36609497-B50892C3-9735-41EE-8FC0-41D795356B4D Q36956080-C55763FE-EAAE-403C-A1E3-EF761201AFE4 Q37087480-70D49CA4-0C37-44D7-A859-C688A4BD9584 Q38130715-D60822D3-D185-4B58-89FA-0CCFE6DB21A7 Q38156321-82EED2AE-ED8D-4F82-B8C9-E226B7630B52 Q38195069-CEB97C0B-D2E1-4F54-888E-36AFEDA8D9FB Q38571499-2F997183-1A73-48F0-ABFA-150429D8EFC7 Q38966367-A643E4C6-2678-4C1F-A9EE-F56477C38C30 Q39120027-0A8CCBAC-2A2A-479E-BF38-86B6EAF1C39B Q40840465-A801BE91-397C-45E8-B104-AD946C8EBBAC Q41488881-E7E87D84-EECB-42D0-B268-28C56B5841FC Q42131318-B8AC63CC-D9EA-46A7-B0CD-7672C5574608 Q47613867-807D0AED-BA9E-4FD4-A8F2-2EEF5200A3FE Q48137867-5016C95A-4E93-418C-803B-BC651E4DFED8 Q53802660-83D46EA4-D862-4C06-B448-EBE47B76ADEF

P2860

Is the GAIN Act a turning point in new antibiotic discovery?

http://www.wikidata.org/entity/Q42268705

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Is the GAIN Act a turning point in new antibiotic discovery?

@en

Is the GAIN Act a turning point in new antibiotic discovery?

@nl

type

label

Is the GAIN Act a turning point in new antibiotic discovery?

@en

Is the GAIN Act a turning point in new antibiotic discovery?

@nl

prefLabel

Is the GAIN Act a turning point in new antibiotic discovery?

@en

Is the GAIN Act a turning point in new antibiotic discovery?

@nl

P1433

Q42268705-1C1932FE-D73C-4EEE-86B4-640BB8EB6A76

P1476

Q42268705-BF0FB738-203A-4B13-8C2F-48A0BF9C7A43

P2093

Q42268705-E1D67971-520A-48F0-936A-B74C8417E93E

P2860

Q42268705-09DD3BC5-73A9-44FF-9124-15AE888BBBF8

Q42268705-0C3A337B-470B-411B-A484-B34ED1C085C3

Q42268705-0CE8AFFC-B671-456E-BB39-035F54362AE6

Q42268705-0D6DA36A-7B64-41EA-BEB8-FEB14043074A

Q42268705-12D0E93D-3BA3-419F-99E4-7547C926DD28

Q42268705-13575418-97F6-4BBC-95B3-44B08A809729

Q42268705-2268F0E6-7AB7-4D30-AA93-064CBBDBD8D0

Q42268705-41970A75-9922-4FE7-9295-67D43E5D9ADD

Q42268705-440EBB7C-1B8F-4C39-AD96-78DD14F63D7A

Q42268705-4E623B91-8E02-49C5-84E5-85CD57CD9C8D

P304

Q42268705-EB8E572F-E14E-40A4-BDCA-DC21E08FD607

P31

Q42268705-4C49E624-3D0C-47FA-A9BB-E9ED11F6955B

P356

Q42268705-060A2D43-689A-4C9B-B277-26623DB40A64

P433

Q42268705-5F25FBCE-BCEA-4DB2-928E-C3CD22ADA13C

P478

Q42268705-D1480146-D73F-4E0B-9AA1-61FF55DF59CB

P577

Q42268705-4D73F716-CEB0-4C75-A1CA-8C5D2B59BE46

P698

Q42268705-1E7E59AF-D2CA-4F86-B96B-F3D548B4682A

P921

Q42268705-63D58256-59DA-4DD6-B66E-AEE81E976E2B

P356

P1433

Canadian Journal of Microbiology

P1476

Is the GAIN Act a turning point in new antibiotic discovery?

@en

P2093

Eric D Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound

Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry

The genetic landscape of a cell

Diarylquinolines target subunit c of mycobacterial ATP synthase

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Drugs for bad bugs: confronting the challenges of antibacterial discovery

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

The chemical genomic portrait of yeast: uncovering a phenotype for all genes

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

P304

153-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1139/CJM-2013-0089

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23540332

http://www.w3.org/2001/XMLSchema#string

P921